Bullous Pemphigoid clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for

  • Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

    Sorry, not yet accepting patients

    To evaluate the efficacy of rituximab combined with omalizumab in achieving sustained complete remission, evaluated by Bullous Pemphigoid Disease Area Index (BPDAI) in patients with bullous pemphigoid (BP) at Week 24 in patients with active moderate-to-severe BP refractory to rituximab therapy alone.

    at UC Davis

Our lead scientists for Bullous Pemphigoid research studies include .

Last updated: